US$ 28.91
aod9604 inhibits lipogenesis adipocytes FABP4 Controls Fat Mass Expandability (Adipocyte Size and Number) through Inhibition of CD36/SR-B2 Signalling AOD-9604 5mg Research Peptide |
Description
At the molecular level, reduced NNMT activity shifts cellular methylation patterns, potentially altering epigenetic modifications via changes in SAM/S-adenosylhomocysteine (SAH) ratios

With its unique ability to stimulate lipolysis and inhibit lipogenesis, AOD-9604 is ideal for those individuals who have discontinued GLP-1 therapy

The science looked promising and the safety profile seemed reasonable

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit
